AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys

AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys

N-methyl-D-aspartate (NMDA) receptors have been implicated in L-Dopa-induced dyskinesias (LID) in Parkinson’s disease patients, but the use of antagonists that directly inhibit this receptor is associated with severe side effects. L-4-chlorokynurenine (4-Cl-KYN or AV-101) is a pro-drug of 7-chloroky...

Full description

Bibliographic Details
Main Authors: Mélanie Bourque, Laurent Grégoire, Waseema Patel, David Dickens, Ralph Snodgrass, Thérèse Di Paolo
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cells
Subjects:
L-4-chlorokynurenine
AV-101
MPTP
dyskinesias
NMDA receptors
Parkinson’s disease
Online Access:https://www.mdpi.com/2073-4409/11/22/3530

Similar Items

Similar Items